Several regulatory guidances on the use of physiologically based pharmacokinetic (PBPK)
analyses and physiologically based biopharmaceutics model (s)(PBBM (s)) have been …

Changes in the pharmacokinetic and resulting pharmacodynamic properties of drugs are
common in many chronic liver diseases, leading to adverse effects, drug interactions and …

Liver cirrhosis is a chronic disease that affects the liver structure, protein expression, and
overall metabolic function. Abundance data for drug-metabolizing enzymes and transporters …

Hepatic impairment (HI) is known to modulate drug disposition and may lead to elevated
plasma exposure. The aim of this study was to quantitate the in vivo OATP1B‐mediated …

Abstract Background and Aims Sarcopenia is associated with poor prognosis, but its role in
older patients with intrahepatic cholangiocarcinoma (ICC) is unclear. We aimed to evaluate …

Nonalcoholic fatty liver disease (NAFLD), representing a clinical spectrum ranging from
nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), is rapidly evolving …

This review assesses how publications interpret factors that influence the serum or plasma
albumin (PA) level in prognostic indices, focusing on inflammation and nutrition. On …

Abstract Model-based assessment of drug pharmacokinetics in liver disease requires
quantification of abundance and disease-related changes in hepatic enzymes and …

The greater utilization and acceptance of physiologically‐based pharmacokinetic (PBPK)
modeling to evaluate the potential metabolic drug–drug interactions is evident by the …

Patho‐physiological changes in liver cirrhosis create portacaval shunts that allow blood flow
to bypass the hepatic portal vein into the systemic circulation affecting drug …